KinasePro

Kinase Chemistry – Just a year and a half behind the times.

Subtle… Interesting… and thoroughly Swiss

Posted by kinasepro on June 13, 2007

WO/2007/062805 is a ‘multi-target’ application from Novartis that tags the earlier WO/2006/050946 with the Gleevec H1.

O=C(NC1=CC=C(C)C(NC2=C3C(N(C4=CC=C(N5CCOCC5)C=C4)N=C3)=NC=N2)=C1)C6=CC=CC(C(F)(F)F)=C6

Claim 11 suggests a few targets on their minds in addition to the titled Vegf / Ephb4:

11. The use according to claim 10, where the protein kinase modulation responsive disease is one or more diseases selected from the group consisting of diseases, that respond to the inhibition of one or more protein tyrosine kinases selected from abl kinase, especially v-abl or c-abl kinase, kinases from the family of the src kinases, especially c-src kinase, b-raf (V599E) and/or especially RET-receptor kinase or Ephrin receptor kinases, or mutated forms thereof.

Advertisements

One Response to “Subtle… Interesting… and thoroughly Swiss”

  1. milkshake said

    what’s so Swiss about this patent – does it have holes?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: